NCT01513369 - Ferric Carboxymaltose in Type 2 Diabetes Mellitus (T2DM) Patients With Iron Deficiency | Biotech Hunter

Enrollment

152

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

October 31, 2018

Study Completion Date

April 30, 2019

Conditions

Type 2 Diabetes MellitusIron Deficiency

Interventions

DRUG

ferric carboxymaltose

Dose:according to SmPC Duration: 12 weeks; Frequency: at week 1 and again at week 5 (if again indicated according to principal inclusion criteria); Application: intravenous

DRUG

NaCl (0,9%)

Duration: 12 weeks; Frequency: at week 1 and again at week 5 (if again indicated according to principal inclusion criteria); Application: intravenous

Trial Locations (6)

30625

Medizinische Hochschule Hannover Klinisches Forschungszentrum CRC, Hanover

32545

Gemeinschaftspraxis Dres. Grüneberg, Mehring, Stude, Herne

Herz- und Diabeteszentrum NRW Ruhr-Universität Bochum, Bad Oeynhausen

69115

Diabetesinstitut Heidelberg, Heidelberg

01307

Univesitätsklinikum Carl Gustav Carus, Dresden

Studienzentrum Professor Hanefeld Abakus Büropark, Dresden